Skip to content
Triangle logo TriangleGet started
← recurrent Primary Central Nervous System Lymphoma

NCT01973062 · STUDY IN CONTEXT

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids

Only one patient registered. No patient data analyzed

→

secondary · POSTED

The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI

Only one patient registered. No patient data analyzed

→

secondary · POSTED

The number of patients alive up to two years after treatment

Only one patient registered. No patient data analyzed

→

secondary · POSTED

Number of patients with toxicities related to the study drug

Only one patient registered. No patient data analyzed

→

secondary · POSTED

Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data

Only one patient registered. No patient data analyzed

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
nct id
NCT01973062
trial label
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
applicability
unclear
applicability note
Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
5
harms Count
1
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0000
    source section id
    NCT01973062-om-0000
    source outcome index
    0
    endpoint
    Radiographic Response Assessed by MRI or FDG-PET/MRI
    endpoint definition
    Number of patients with at least a 50% reduction in tumor size on a MRI scan with stable or decreasing dose of corticosteroids
    time origin
    Up to 2 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Only one patient registered. No patient data analyzed
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0001
    source section id
    NCT01973062-om-0001
    source outcome index
    1
    endpoint
    Progression Free Survival
    endpoint definition
    The number of patients without an unequivocal increase in tumor size or the appearance of new lesions by MRI
    time origin
    Up to 2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Only one patient registered. No patient data analyzed
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0002
    source section id
    NCT01973062-om-0002
    source outcome index
    2
    endpoint
    Overall Survival
    endpoint definition
    The number of patients alive up to two years after treatment
    time origin
    Up to 2 years
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Only one patient registered. No patient data analyzed
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0003
    source section id
    NCT01973062-om-0003
    source outcome index
    3
    endpoint
    Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.
    endpoint definition
    Number of patients with toxicities related to the study drug
    time origin
    Up to 30 days following the last dose of study treatment
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Only one patient registered. No patient data analyzed
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0004
    source section id
    NCT01973062-om-0004
    source outcome index
    4
    endpoint
    Dosimetry Calculations of Yttrium Y 90 Ibritumomab Tiuxetan Assessed by PET/MRI
    endpoint definition
    Number of Gy delivered to each tumor as calculated using the MIRD dosimetry formula on PET data
    time origin
    At day 11
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Only one patient registered. No patient data analyzed
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    regimen
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01973062-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    regimen
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01973062-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    regimen
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01973062-om-0002#groups/OG000
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    regimen
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01973062-om-0003#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    outcome key
    om-0004
    arm key
    OG000
    arm label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    regimen
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    analyzed count
    0
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT01973062-om-0004#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-primary-central-nervous-system-lymphoma-recurrent-8dadeeb5
    nct id
    NCT01973062
    harm key
    EG000
    source section id
    NCT01973062-ae
    event group key
    EG000
    event group label
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
    serious affected
    0
    serious at risk
    1
    other affected
    0
    other at risk
    1
    frequency threshold
    5
    collection period
    Source null
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice